Immunovant (IMVT) Other Accumulated Expenses (2023 - 2026)

Immunovant has reported Other Accumulated Expenses for 4 years, with the latest figure at $175000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 35.9% year-over-year to $175000.0; the trailing twelve-month figure through Mar 2026 stood at $175000.0 (down 35.9% YoY), and the FY2026 full-year result was $175000.0, down 35.9% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $175000.0, down from $273000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $350000.0 in Q1 2023, with the low at $15000.0 in Q1 2024.
• Historically, Other Accumulated Expenses has averaged $203250.0 across 4 years, with a median of $224000.0 in 2025.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses plunged 95.71% — and 2025, when it surged 1720.0%.
• Immunovant's Other Accumulated Expenses stood at $350000.0 in 2023, then sank by 95.71% to $15000.0 in 2024, then surged by 1720.0% to $273000.0 in 2025, then tumbled by 35.9% to $175000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $175000.0 (Q1 2026), $273000.0 (Q1 2025), and $15000.0 (Q1 2024), per Business Quant data.